Home » Stocks » PLRX

Pliant Therapeutics, Inc. (PLRX)

Stock Price: $29.25 USD -1.90 (-6.10%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 1.14B
Revenue (ttm) 15.05M
Net Income (ttm) -75.42M
Shares Out 35.65M
EPS (ttm) -3.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $29.25
Previous Close $31.15
Change ($) -1.90
Change (%) -6.10%
Day's Open 31.25
Day's Range 28.50 - 32.00
Day's Volume 218,091
52-Week Range 19.43 - 43.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021

3 days ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics fo...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

1 month ago - GlobeNewsWire

- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies ...

4 months ago - GlobeNewsWire

PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.

5 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel ther...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

8 months ago - PRNewsWire

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

9 months ago - PRNewsWire

There's a chance that it could become an even bigger success story.

11 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...

11 months ago - PRNewsWire

Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.

11 months ago - GuruFocus

Investors are excited about the biotech's prospects, but the company still has a long road ahead.

11 months ago - The Motley Fool

Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.

11 months ago - Market Watch

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also deve... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 2020
CEO
Bernard Coulie
Employees
78
Stock Exchange
NASDAQ
Ticker Symbol
PLRX
Full Company Profile

Financial Performance

In 2020, PLRX's revenue was $41.82 million, a decrease of -26.70% compared to the previous year's $57.05 million. Losses were -$41.53 million, 6,482.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 76.07% from the latest price.

Price Target
$51.50
(76.07% upside)
Analyst Consensus: Buy